Alzheimer's Disease

Anavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANAVEX®2- 73 at 2017 Clinical Trials on Alzheimer’s Disease Meeting

NEW YORK, November 4, 2017 – Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today presented new clinical pharmacokinetic (PK) and pharmacodynamic (PD)…